Senti Biosciences, Inc. (NASDAQ:SNTI) Sees Significant Decrease in Short Interest

Senti Biosciences, Inc. (NASDAQ:SNTI) was the target of a significant decline in short interest during the month of March. As of March 15th, there was short interest totalling 39,600 shares, a decline of 43.8% from the February 28th total of 70,400 shares. Based on an average trading volume of 62,300 shares, the days-to-cover ratio is currently 0.6 days. Approximately 0.4% of the company’s stock are sold short.

Analysts Set New Price Targets

Separately, Chardan Capital reissued a “buy” rating and set a $10.00 price target on shares of Senti Biosciences in a research report on Monday, December 2nd.

Senti Biosciences Stock Up 3.0 %

Shares of NASDAQ:SNTI traded up $0.10 during midday trading on Friday, hitting $3.43. The stock had a trading volume of 9,037 shares, compared to its average volume of 784,513. The company has a market cap of $16.57 million, a P/E ratio of -0.22 and a beta of 2.52. Senti Biosciences has a 12 month low of $1.52 and a 12 month high of $16.94. The business’s 50-day simple moving average is $3.88 and its 200-day simple moving average is $3.47.

Senti Biosciences (NASDAQ:SNTI) last announced its quarterly earnings data on Thursday, March 20th. The company reported ($0.67) EPS for the quarter, beating analysts’ consensus estimates of ($3.13) by $2.46. The firm had revenue of $5.86 million during the quarter, compared to the consensus estimate of $2.80 million. As a group, equities analysts predict that Senti Biosciences will post -14.54 earnings per share for the current year.

Hedge Funds Weigh In On Senti Biosciences

An institutional investor recently bought a new position in Senti Biosciences stock. Virtu Financial LLC bought a new position in shares of Senti Biosciences, Inc. (NASDAQ:SNTI) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 13,356 shares of the company’s stock, valued at approximately $47,000. Virtu Financial LLC owned about 0.28% of Senti Biosciences at the end of the most recent quarter. 25.73% of the stock is owned by hedge funds and other institutional investors.

Senti Biosciences Company Profile

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.